Chevrolet GM 22732841 Right Switch Button Control Wheel-Cruise Steering OEM Other Car & Truck Computers, Chips & Cruise Control


  1. Home
  2. Chevrolet GM 22732841 Right Switch Button Control Wheel-Cruise Steering OEM
  1. facebook
  2. twitter
  3. linkedin
  4. pinterest
Chevrolet GM OEM Steering Wheel-Cruise Control Button Switch Right 22732841
Condition: New Genuine OEM: Yes
Fitment Footnotes: Diag Ref #5;W/o Radio Controls; Warranty: 1 Year
Superseded Part Number: 22719896 Quantity: 1
Other Part Number: 22719896 SKU: 300:22732841
Item Name: Cruise Switch Brand:

GM

Part Ref# on Diagram: ONLY PART REFERENCE #5 ON THE DIAGRAM IS INCLUDED Manufacturer Part Number:

22732841

Quantity Needed: 1 Category 2: Steering Wheel
Category 1: Steering Column Fitment Type: Direct Replacement
Placement on Vehicle: Right Category 3: Steering Wheel & Trim
UPC:

Does not apply






published on tue nov 09 2021

Chevrolet GM 22732841 Right Switch Button Control Wheel-Cruise Steering OEM Other Car & Truck Computers, Chips & Cruise Control

gandhi, s., klein, j., robertson, a., pena-hernandez, m. a.,

Chevrolet GM 22732841 Right Switch Button Control Wheel-Cruise Steering OEM Other Car & Truck Computers, Chips & Cruise Control

lin, m. j., roychoudhury, p., lu, p., fournier, j., ferguson, d., mohamed bakhash, s. a., muenker, m. c., srivathsan, a., wunder, e. a., kerantzas, n., wang, w., pyle, a., wilen, c. b., ogbuagu, o., greninger ,, a. l., iwasaki, a., schulz, w. l., ko, a. i.

sars-cov-2 remdesivir resistance mutations have been generated in vitro but have not been reported in patients receiving treatment with the antiviral agent. we present a case of an immunocompromised patient with acquired b-cell deficiency who developed an indolent, protracted course of sars-cov-2 infection. remdesivir therapy alleviated symptoms and produced a transient virologic response, but her course was complicated by recrudescence of high-grade viral shedding. whole genome sequencing identified a mutation, e802d, in the nsp12 rna-dependent rna polymerase which was not present in pre-treatment specimens. in vitro experiments demonstrated that the mutation conferred a ~6-fold increase in remdesivir ic50 but resulted in a fitness cost in the absence of remdesivir. sustained clinical and virologic response was achieved after treatment with casirivimab-imdevimab. although the fitness cost observed in vitro may limit the risk posed by e802d,

, this case illustrates the importance of monitoring for remdesivir resistance and the potential benefit of combinatorial therapies in immunocompromised patients with sars-cov-2 infection.

509
1.2k
EVGENIA.RU RSS